Persons involved in the project:
Senior consultant and professor Eivind Berge
Phone: +47 22119100
Prof Berge was responsible for the health-economic evaluation of thrombolytic treatment for stroke in the UK, commissioned by the NHS R&D Health Technology Assessment Programme, and is currently involved in the cost-/utility-analyses of the Scandinavian Candesartan Acute Stroke Trial (SCAST, Lancet 2011) and the Third Interntional Stroke Trial (IST-3). He is also leader of the health economics analysis in the EU-funded PRECIOUS trial.
Associate professor Hans Olav Melberg
Phone: +47 93658818
Ass Prof Melberg is Leader of the OUS research group in economic evaluation, and has been involved in a number of healh-economic evaluations commisioned by the Norwegian Government, Ministry of Finance, Ministry of Health, and the Norwegian Directorate of Health. He is currently partner in a number of international collaborations, including a project led by Prof Zeke Emmanuel (University of Pennsylvania, USA), and the Addictions and Lifestyle in Contemporary Europe – Reframing Addictions Project (ALICE-RAP), financed by the EU 7th Framework Programme.
Researcher Linn Kleven
Phone: +47 97651340
Researcher Kleven is a member of the OUS research group in economic evaluation, which provides support to research groups/clinicians/PhD candidates at the OUS and other hospitals within the South-Eastern Norway Regional Health Authority. She is also a part of the economic evaluation team in IST-3.
Description of the institution:
Oslo universitetssykehus HF (OUS) has a nationwide responsibility for a number of national and multi-regional assignments and has several national centers of competence. OUS is responsible for approximately 50 percent of all medical and healthcare research conducted at Norwegian hospitals and is a significant role player within the education of a large variety of health care personnel. The hospital is Scandinavia’s largest and each year carries out more than 1.2 million patient treatments. The aim of the hospital is to create a well functioning and efficient local hospital, to strengthen highly specialized medicine, conduct research and provide education and innovation on international levels.
Oslo University Hospital is leader of WP6 (Health economic assessment and gender analysis).